Market Place
Sourcing Support
Stoke Therapeutics to Present at 43rd Annual J.P. Morgan Conference
08 Jan 2025 //
BUSINESSWIRE
Stoke Therapeutic Presents Data On Zorevunersen For Dravet Syndrome
06 Dec 2024 //
BUSINESSWIRE
Stoke Gets FDA Breakthrough Designation For Zorevunersen In Dravet
04 Dec 2024 //
BUSINESSWIRE
Stoke Therapeutics to Data on Zorevunersen for Dravet Syndrome
02 Dec 2024 //
BUSINESSWIRE
Stoke Therapeutics Reports Q3 Financial Results & Updates
05 Nov 2024 //
BUSINESSWIRE
Stoke Presents Zorevunersen Data For Dravet Syndrome
10 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer
04 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present Data on Zorevunersen at European Epilepsy Congress
03 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at Upcoming Investor Conferences in September
03 Sep 2024 //
BUSINESSWIRE
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Aug 2024 //
BUSINESSWIRE
Stoke Therapeutics Reports Q2 Results And Provides Business Updates
07 Aug 2024 //
BUSINESSWIRE
Stoke`s Dravet Syndrome Med Released From Partial Clinical Hold
07 Aug 2024 //
FIERCE BIOTECH
Stoke Therapeutics Reports Inducement Grants Under Nasdaq Rule 5635(c)(4)
16 Jul 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at Upcoming Investor Conferences in June
03 Jun 2024 //
BUSINESSWIRE
Stoke Therapeutics Reports Inducement Grants Under Nasdaq 5635(c)(4)
17 May 2024 //
BUSINESSWIRE
Stoke Therapeutics reports first quarter financials and updates.
06 May 2024 //
BUSINESSWIRE
Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer
29 Apr 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at the 23rd Annual NVH Conference
04 Apr 2024 //
BUSINESSWIRE
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering
27 Mar 2024 //
BUSINESSWIRE
Stoke Therapeutics Announces Proposed Public Offering
26 Mar 2024 //
BUSINESSWIRE
Stoke’s shares up 90% as epilepsy drug cuts convulsive seizures
26 Mar 2024 //
FIERCE BIOTECH
Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
25 Mar 2024 //
BUSINESSWIRE
Stoke Announces Data of the STK-001 for the Treatment of Dravet Syndrome
25 Mar 2024 //
BUSINESSWIRE
Stoke Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17 Jan 2024 //
BUSINESSWIRE
Stoke Highlights Strategic Priorities and Anticipated Milestones for 2024
08 Jan 2024 //
BUSINESSWIRE
Stoke Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
04 Jan 2024 //
BUSINESSWIRE
Stoke Therapeutics Presents Data From Multiple Studies of Children
01 Dec 2023 //
BUSINESSWIRE
Stoke to Present Data from the Company’s Dravet Syndrome Clinical Program
21 Nov 2023 //
BUSINESSWIRE
Stoke Therapeutics Reports Third Quarter Financial Results
07 Nov 2023 //
BUSINESSWIRE
Stoke Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
17 Oct 2023 //
BUSINESSWIRE
Stoke Therapeutics to Participate in 2023 Cantor Global Healthcare Conference
21 Sep 2023 //
BUSINESSWIRE
Stoke Therapeutics Appoints Ian Smith to its Board of Directors
20 Sep 2023 //
BUSINESSWIRE
Stoke Presents Data Related to the Ongoing Clinical Development of STK-001
05 Sep 2023 //
BUSINESSWIRE
Stoke Reports Second Quarter Financial Results and Provides Business Updates
07 Aug 2023 //
BUSINESSWIRE
Stoke shares drop 30% as Dravet drug posts high adverse events
25 Jul 2023 //
FIERCE BIOTECH
Stoke Therapeutics Announces Positive Data from Patients Treated with STK-001
25 Jul 2023 //
BUSINESSWIRE
Stoke to Host Webinar to Present New Data from Patients Treated with STK-001
21 Jul 2023 //
BUSINESSWIRE
Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing
16 Jun 2023 //
BUSINESSWIRE
Stoke Reports First Quarter Financial Results and Provides Business Updates
04 May 2023 //
PRESS RELEASE
Stoke Therapeutics to Present at the BofA Securities Health Care Conference
03 May 2023 //
BUSINESSWIRE
Stoke Therapeutics Receives Authorization to Initiate a Ph 1/2 Study of STK-002
25 Apr 2023 //
BUSINESSWIRE
Stoke Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001
15 Mar 2023 //
BUSINESSWIRE
FDA partially lifts dosing hold on Stoke`s pediatric Dravet syndrome study
15 Mar 2023 //
ENDPTS
Stoke Reports Fourth Quarter and Full Year 2022 Financial Results
06 Mar 2023 //
BUSINESSWIRE
Stoke Therapeutics to Participate at Upcoming March Investor Conferences
27 Feb 2023 //
BUSINESSWIRE
Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference
07 Feb 2023 //
BUSINESSWIRE
Stoke Highlights Strategic Priorities and Anticipated Milestones for 2023
09 Jan 2023 //
BUSINESSWIRE
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Ph 1/2a
02 Dec 2022 //
BUSINESSWIRE
Stoke Therapeutics to Present Data from the Company’s Dravet Syndrome Program
29 Nov 2022 //
BUSINESSWIRE
Stoke stumbles on latest interim readout for Dravet syndrome drug
14 Nov 2022 //
FINANCE YAHOO
Stoke Reports Third Quarter Financial Results and Provides Business Updates
14 Nov 2022 //
BUSINESSWIRE
Stoke teases data for possible PhIII dose in lead Dravet syndrome program
14 Nov 2022 //
ENDPTS
Stoke to Host Webinar Call to Present Interim Data Ph1/2a of STK-001
10 Nov 2022 //
BUSINESSWIRE
Stoke Therapeutics Reports Second Quarter Financial Results
08 Aug 2022 //
BUSINESS WIRE
Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
BUSINESSWIRE
Stoke Therapeutics Reports First Quarter Financial Results
10 May 2022 //
BUSINESSWIRE
Stoke Therapeutics Presents New In-Vivo Data on STK-002
02 May 2022 //
BUSINESSWIRE
Stoke Therapeutics to Present at ARVO 2022 Annual Meeting
07 Apr 2022 //
BUSINESSWIRE
Stoke Tx Reports Q4 and Full Year 2021 Financial Results
10 Mar 2022 //
BUSINESSWIRE
Stoke Tx to Participate in the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
BUSINESSWIRE
